LabCorp has expanded access to its at-home collection test kit to individuals nationwide who have symptoms consistent with coronavirus disease 2019 and those without symptoms who may have been exposed to the virus.
The impact of COVID-19 on the global health system and economy will likely result in large-scale changes in zoonotic disease prevention preparedness.
Haymarket Medical Network, a part of business media company Haymarket Media, Inc., is proud to join the Ad Council’s first ever Private Marketplace (PMP) along with other partners Cadreon, The Trade Desk and Acxiom.
The American Board of Internal Medicine announced that certified physicians who have a Maintenance of Certification requirement due in 2020 will now have until the end of 2021 to complete it.
A phase 3 study evaluating Ultomiris (ravulizumab-cwvz; Alexion) in hospitalized patients with COVID-19 is expected to begin in May.
The FDA has granted Fast Track designation to MRT5005, an inhaled messenger RNA (mRNA) therapeutic being investigated for the treatment of cystic fibrosis.
Remunity is indicated for continuous subcutaneous delivery of Remodulin to treat pulmonary arterial hypertension in patients ≥22 years of age.
The FDA has granted Orphan Drug designation to ARV-1801 (sodium fusidate; Arrevus) for the treatment of pulmonary exacerbations in patients with cystic fibrosis.
The FDA has granted 510(k) clearance to the Hyperfine system, a bedside magnetic resonance imaging system.
The FDA has accepted for review a supplemental New Drug Application for Recarbrio™, to treat adult patients with hospital-acquired and ventilator-associated bacterial pneumonia.
